Want to see SE:NEEMS.B full AI Analyst Report?

Scandinavian ChemoTech AB Class B (NEEMS.B) Price & Analysis

1 Followers

NEEMS.B Stock Chart & Stats

kr4.79

-kr0.03(-2.80%)

At close: Mar 06 4:00 PM EST

kr4.79

-kr0.03(-2.80%)

Day’s Range― - ―

52-Week Rangekr2.70 - kr7.76

Previous CloseN/A

VolumeN/A

Average Volume (3M)54.14K

Market Cap

kr79.96M

Enterprise Valuekr95.90

Total Cash (Recent Filing)kr1.46M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta-0.67

Next Earnings

Oct 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.25

Shares Outstanding23,802,313

10 Day Avg. Volume61,695

30 Day Avg. Volume54,140

Financial Highlights & Ratios

PEG Ratio0.35

Price to Book (P/B)37.86

Price to Sales (P/S)9.82

P/FCF Ratio-28.84

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)kr19.10M

Bulls Say, Bears Say

Bulls Say

Strong Revenue GrowthRapid revenue expansion indicates increasing adoption of the IQWave/TSE platform and broader commercial reach. If growth continues, greater procedure volumes could improve operating leverage and support the transition toward sustainable profitability.

Improved Gross MarginThe shift to positive gross margin suggests the product and consumables model is becoming more economically viable. Sustained gross profitability would provide a stronger base for covering operating expenses as the installed customer base and treatment volumes expand.

Debt-free Balance SheetMinimal financial leverage limits refinancing needs, interest expense and sensitivity to lending conditions. This gives the company greater flexibility to invest in commercialization and clinical adoption, although the benefit depends on preserving liquidity while losses continue.

Bears Say

Persistent Operating LossesDespite strong revenue growth and positive gross margin, operating costs still exceed gross profit. Persistent losses indicate that the business has not yet achieved operating leverage, leaving profitability dependent on further scale, cost control and adoption.

Negative Free Cash FlowThe company is not currently funding its operations internally, so continued commercialization and development may require external capital. Even though cash burn improved from earlier periods, sustained negative free cash flow remains a material financing risk.

Eroding Equity BaseA shrinking equity base reduces the company’s financial cushion and reflects the cumulative effect of losses. Combined with negative cash generation, this can increase reliance on future funding and create dilution or execution risk before the business reaches breakeven.

NEEMS.B FAQ

What was Scandinavian ChemoTech AB Class B’s price range in the past 12 months?

Scandinavian ChemoTech AB Class B lowest stock price was kr2.70 and its highest was kr7.76 in the past 12 months.

What is Scandinavian ChemoTech AB Class B’s market cap?

Scandinavian ChemoTech AB Class B’s market cap is kr79.96M.

When is Scandinavian ChemoTech AB Class B’s upcoming earnings report date?

Scandinavian ChemoTech AB Class B’s upcoming earnings report date is Oct 27, 2026 which is in 60 days.

How were Scandinavian ChemoTech AB Class B’s earnings last quarter?

Scandinavian ChemoTech AB Class B released its earnings results on Aug 11, 2026. The company reported -kr0.102 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Scandinavian ChemoTech AB Class B overvalued?

According to Wall Street analysts Scandinavian ChemoTech AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Scandinavian ChemoTech AB Class B pay dividends?

Scandinavian ChemoTech AB Class B does not currently pay dividends.

What is Scandinavian ChemoTech AB Class B’s EPS estimate?

Scandinavian ChemoTech AB Class B’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Scandinavian ChemoTech AB Class B have?

Scandinavian ChemoTech AB Class B has 23,802,313 shares outstanding.

What happened to Scandinavian ChemoTech AB Class B’s price movement after its last earnings report?

Scandinavian ChemoTech AB Class B reported an EPS of -kr0.102 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.079%.

Which hedge fund is a major shareholder of Scandinavian ChemoTech AB Class B?

Currently, no hedge funds are holding shares in SE:NEEMS.B

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Scandinavian ChemoTech AB Class B

Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and Animal Care. The company offers IQWave, an electroporation that generates a tumour-specific electrical stimulation; and veterinary medicines under the vetIQur name. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.